In:
The Journal of Immunology, The American Association of Immunologists, Vol. 192, No. 1_Supplement ( 2014-05-01), p. 52.15-52.15
Abstract:
Chronic kidney disease (CKD) is a progressive loss in renal function, which severity is classified in five stages, with stage 1 being the mildest and stage 5 being a severe illness evolving to hemodialysis (HD). Chronic inflammatory state in HD and CKD patients (pts) may contribute to the development of bone disease through the increase of osteoclasts (OCs), the bone resorbing cells. In pathological condition, immune cells and inflammatory cytokines belonging to tumor necrosis factor superfamily, such as LIGHT and RANKL, play a key role in osteoclastogenesis. The aim of our study was to evaluate the osteoclastogenic potential of unfractionated and T cell-depleted PBMCs from CKD and HD pts. We also evaluated the presence of circulating osteoclast precursors (CD14+/CD16+) and characterized the immune cell subsets for LIGHT and RANKL expression through flow cytometry and RT-PCR. PBMCs from HD and CKD pts (stage IV-V) showed a spontaneous osteoclastogenesis in vitro (80±7). Conversely, exogenous cytokines were essential to trigger and sustain osteoclastogenesis in CKD pts (stage I-II) and controls (10±4). It correlated with a significant increase of both LIGHT and RANKL expression on CD4+ T cells as well as CD14+CD16+ monocytes in HD and CKD pts (stage IV-V) compared to controls (p & lt;0.005). LIGHT and RANKL may represent a new link between immune cells activation and bone-associated disease in CKD and HD pts suggesting new potential therapeutic targets in the setting of these pts.
Type of Medium:
Online Resource
ISSN:
0022-1767
,
1550-6606
DOI:
10.4049/jimmunol.192.Supp.52.15
Language:
English
Publisher:
The American Association of Immunologists
Publication Date:
2014
detail.hit.zdb_id:
1475085-5
Permalink